Mirexone is the trade name and generic name of Methylprednisolone Sodium Succinate, which has the efficacy of anti-inflammatory, anti-allergic, immunosuppressive, anti-shock and other effects of the role. Methylprednisolone sodium succinate is a kind of glucocorticoid, which is a common clinical drug; it can be used for the treatment of a variety of diseases, such as adjuvant treatment of rheumatic diseases, acute phase of arthritis, systemic lupus erythematosus, rheumatic myocarditis, urticaria, bronchial asthma, allergic rhinitis, ulcerative colitis, post-transplantation of organs, and some blood system diseases. The use of the drug may cause hypertension, osteoporosis and other adverse reactions, systemic mycobacterial infections and known hypersensitivity to the components of the drug are contraindicated. Application, reduction and discontinuation of methylprednisolone sodium succinate should be carried out under the supervision of a specialized physician. After use, electrolytes, blood pressure, blood glucose and so on should be regularly monitored; pay attention to the observation of whether there is gastrointestinal bleeding; pay attention to regular outpatient follow-up.